Revocation and Determination

of

Statement of Principles

concerning

TINNITUS

ICD-10-AM CODE: H93.1

Veterans’ Entitlements Act 1986

1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act):

(a) revokes Instrument No.8 of 2001; and

(b) determines in its place the following Statement of Principles.

Kind of injury, disease or death

2. (a) This Statement of Principles is about tinnitus and death from tinnitus.

(b) For the purposes of this Statement of Principles, “tinnitus” means a persistent perception of endogenous noise heard in the ear, attracting ICD-10-AM code H93.1

Basis for determining the factors

3. On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that tinnitus and death from tinnitus can be related to relevant service rendered by veterans or members of the Forces.
Factors that must be related to service

4. Subject to clause 6, at least one of the factors set out in clause 5 must be related to any relevant service rendered by the person.

Factors

5. The factors that must exist before it can be said that, on the balance of probabilities, tinnitus or death from tinnitus are connected with the circumstances of a person’s relevant service are:

(a) being exposed to an impulsive noise of at least 140 dBA without adequate ear protection within the 48 hours immediately before the clinical onset of tinnitus; or

(b) being exposed to noise of at least 85 dBA as an 8-hour time-weighted average (TWA) with a 3-dB exchange rate without adequate ear protection for one year immediately before the clinical onset of tinnitus; or

(c) suffering trauma to the auditory apparatus at the time of the clinical onset of tinnitus; or

(d) suffering from sensorineural hearing loss at the time of the clinical onset of tinnitus; or

(e) undergoing a course of treatment with an ototoxic drug from the specified list within the year immediately before the clinical onset of tinnitus; or

(f) undergoing a course of treatment with salicylate or quinine derivatives, for a condition for which the drug cannot be ceased or substituted, at the time of the clinical onset of tinnitus; or

(g) suffering from a source of vascular sound proximal to the affected ear at the time of the clinical onset of tinnitus; or

(h) suffering from an intracranial neoplasm at the time of the clinical onset of tinnitus; or

(i) suffering from otosclerosis at the time of the clinical onset of tinnitus; or

(k) suffering from Meniere’s disease at the time of the clinical onset of tinnitus; or
(m) suffering at least one episode of otitic barotrauma within the 30 days immediately before the clinical onset of tinnitus; or

(n) being exposed to an impulsive noise of at least 140 dBA without adequate ear protection within the 48 hours immediately before the clinical worsening of tinnitus; or

(o) being exposed to noise greater than 85 dBA as an 8-hour time-weighted average (TWA) with a 3-dB exchange rate without adequate ear protection for one year immediately before the clinical worsening of tinnitus; or

(p) suffering trauma to the auditory apparatus at the time of the clinical worsening of tinnitus; or

(q) suffering from sensorineural hearing loss at the time of the clinical worsening of tinnitus; or

(r) undergoing a course of treatment with an ototoxic drug from the specified list within the year immediately before the clinical worsening of tinnitus; or

(s) undergoing a course of treatment with salicylate or quinine derivatives, for a condition for which the drug cannot be ceased or substituted, at the time of the clinical worsening of tinnitus; or

(t) suffering from a source of vascular sound proximal to the affected ear at the time of the clinical worsening of tinnitus; or

(u) suffering from an intracranial neoplasm at the time of the clinical worsening of tinnitus; or

(v) suffering from otosclerosis at the time of the clinical worsening of tinnitus; or

(w) suffering from Meniere’s disease at the time of the clinical worsening of tinnitus; or

(x) suffering at least one episode of otitic barotrauma within the 30 days immediately before the clinical worsening of tinnitus; or

(y) inability to obtain appropriate clinical management for the tinnitus.
Factors that apply only to material contribution or aggravation

6. Paragraphs 5(n) to 5(y) apply only to material contribution to, or aggravation of tinnitus where the person’s tinnitus was suffered or contracted before or during (but not arising out of) the person’s relevant service; paragraph 8(1)(e), 9(1)(e) or 70(5)(d) of the Act refers.

Inclusion of Statements of Principles

7. In this Statement of Principles if a relevant factor applies and that factor includes an injury or disease in respect of which there is a Statement of Principles then the factors in that last mentioned Statement of Principles apply in accordance with the terms of that Statement of Principles.

Other definitions

8. For the purposes of this Statement of Principles:

   “adequate ear protection” means a device which plugs the outer ear canal or which covers the outside of the ear so as to protect the wearer from harmful noise;

   “an ototoxic drug from the specified list” means one of the following:

   (a) α-difluromethylornithine;
   (b) 6-amino nicotinamide;
   (c) Amikacin;
   (d) Bumetanide;
   (e) Cisplatin;
   (f) Erythromycin;
   (g) Ethacrynic acid;
   (h) Frusemide;
   (i) Gentamicin;
   (j) Kanamycin;
   (k) Misonidazole;
   (l) Neomycin;
   (m) Netilmicin;
   (n) Nitrogen Mustard;
   (o) Streptomycin;
   (p) Tobramycin;
   (q) Vancomycin;
   (r) Vinblastine;
   (s) Vincristine; or
   (t) Viomycin;
“a source of vascular sound” means one of the following:

(a) acquired arteriovenous fistulae;
(b) benign intracranial hypertension;
(c) carotid occlusion;
(d) carotid stenosis;
(e) cerebral atherosclerosis;
(f) glomus jugulare tumour;
(g) intracranial aneurysm; or
(h) Paget’s disease of the skull;

“death from tinnitus” in relation to a person includes death from a terminal event or condition that was contributed to by the person’s tinnitus;

“ICD-10-AM code” means a number assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, 10th revision, Australian Modification (ICD-10-AM), Second Edition, effective date of 1 July 2000, copyrighted by the National Centre for Classification in Health, Sydney, NSW, and having ISBN 1 86487 271 3;

“impulsive noise” means noise which is characterised by a sharp rise and a rapid decay in sound levels and is less than one second in duration;

“intracranial neoplasm” means a neoplasm affecting the brain, meninges, skull or cranial nerves;

“Meniere’s disease” means a clinical condition characterised by fluctuating hearing loss, tinnitus, a sense of fullness in the involved ear associated with recurring attacks of rotational vertigo of sudden onset, often associated with nausea and vomiting;

“otosclerosis” means a primary disorder of the labyrinthine capsule, characterised by new bone formation commonly involving the footplate of the stapes;

“relevant service” means:

(a) eligible war service (other than operational service); or
(b) defence service (other than hazardous service);

“sensorineural hearing loss” means a permanent hearing threshold shift of 25 decibels (dB) or more, at 500, 1000, 1500, 2000, 3000 or 4000
hertz (Hz) due to a defect in the cochlea or the auditory nerve, but excluding congenital deafness;

“terminal event” means the proximate or ultimate cause of death and includes:

(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function;

“trauma to the auditory apparatus” means injury to the tympanic membrane, ear ossicles, cochlea or acoustic nerve caused by trauma to the head;

“time-weighted average (TWA) with 3-dB exchange rate” means the time-weighted average noise exposure level calculated according to the following formulae and shown in the table:

\[
TWA = 10.0 \times \log(D/100) + 85
\]

where \( D \) = daily dose; and

\[
D = [ \frac{C_1}{T_1} + \frac{C_2}{T_2} + \ldots + \frac{C_n}{T_n} ] \times 100
\]

where \( C_n \) = total time of exposure at a specified noise level,
\( T_n \) = exposure duration for which noise at this level becomes hazardous
Table of noise exposure levels and durations based on 3-dBA exchange rate

<table>
<thead>
<tr>
<th>Exposure Level, $L$ (dBA)</th>
<th>Duration, $T$</th>
<th>Exposure Level, $L$ (dBA)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hours</td>
<td>Minutes</td>
</tr>
<tr>
<td>80</td>
<td>25</td>
<td>24</td>
</tr>
<tr>
<td>81</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>82</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>83</td>
<td>12</td>
<td>42</td>
</tr>
<tr>
<td>84</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>85</td>
<td>8</td>
<td>—</td>
</tr>
<tr>
<td>86</td>
<td>6</td>
<td>21</td>
</tr>
<tr>
<td>87</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>88</td>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td>89</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>90</td>
<td>2</td>
<td>31</td>
</tr>
<tr>
<td>91</td>
<td>2</td>
<td>—</td>
</tr>
<tr>
<td>92</td>
<td>1</td>
<td>35</td>
</tr>
<tr>
<td>93</td>
<td>1</td>
<td>16</td>
</tr>
<tr>
<td>94</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>95</td>
<td>—</td>
<td>47</td>
</tr>
<tr>
<td>96</td>
<td>—</td>
<td>37</td>
</tr>
<tr>
<td>97</td>
<td>—</td>
<td>30</td>
</tr>
<tr>
<td>98</td>
<td>—</td>
<td>23</td>
</tr>
<tr>
<td>99</td>
<td>—</td>
<td>18</td>
</tr>
<tr>
<td>100</td>
<td>—</td>
<td>15</td>
</tr>
<tr>
<td>101</td>
<td>—</td>
<td>11</td>
</tr>
<tr>
<td>102</td>
<td>—</td>
<td>9</td>
</tr>
<tr>
<td>103</td>
<td>—</td>
<td>7</td>
</tr>
<tr>
<td>104</td>
<td>—</td>
<td>5</td>
</tr>
<tr>
<td>105</td>
<td>—</td>
<td>4</td>
</tr>
</tbody>
</table>

Source: National Institute of Occupational Safety and Health 1998 Guidelines
Publication No. 98-126

Application

9. This Instrument applies to all matters to which section 120B of the Act applies.

Dated this First day of May 2001

The Common Seal of the Repatriation Medical Authority was affixed to this instrument in the presence of:

KEN DONALD
CHAIRMAN